Headlines about Peregrine Pharmaceuticals (NASDAQ:PPHM) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Peregrine Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.5072488538871 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Peregrine Pharmaceuticals, Inc. (PPHM) registers a price change of 0.62% while Revance Therapeutics, Inc. (RVNC … - Stocks Gallery (stocksgallery.com)
- Placing the Spotlight on Peregrine Pharmaceuticals Inc (PPHM): Technical Stock Update - Sparta Review (spartareview.com)
- Keep Your Active Eyes on Peregrine Pharmaceuticals, Inc. (PPHM) - Wall Street Morning (wallstreetmorning.com)
- Active Stocks on Watch: Peregrine Pharmaceuticals Inc (PPHM) and … - Sparta Review (spartareview.com)
A number of research firms recently issued reports on PPHM. Zacks Investment Research lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. Noble Financial reaffirmed a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Monday, July 31st. ValuEngine lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 9th. Finally, BidaskClub raised Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Peregrine Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $5.25.
Shares of Peregrine Pharmaceuticals (NASDAQ PPHM) opened at 3.24 on Friday. The company has a 50-day moving average price of $4.12 and a 200-day moving average price of $4.12. Peregrine Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $5.78. The stock’s market cap is $146.02 million.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last issued its quarterly earnings data on Friday, July 14th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.09. The firm had revenue of $17.90 million for the quarter, compared to analyst estimates of $22.57 million. Peregrine Pharmaceuticals had a negative net margin of 48.86% and a negative return on equity of 63.75%. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. On average, equities analysts expect that Peregrine Pharmaceuticals will post ($0.40) earnings per share for the current fiscal year.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
